Other estrogen-responsive genes upregulated in CTCF-altered cancers, namely SPDEF, TFF3 and PIGR, are also components of these gene signatures, indicating that loss of CTCF could be an important factor determining endometrial cancer progression and pathology. This evidence concerns the gene TFF3 and endometrial cancer.